ClinicalTrials.gg
RecruitingNCT05906992Updated May 22, 2024

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 3 interventional study of CT-P53 and US-Ocrevus in Relapsing-remitting Multiple Sclerosis, sponsored by Celltrion. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.

Planned enrollment
5th of 10
512 · median 404
Started
2024
the only one that year
Phase 3
6 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Celltrion

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 5th largest by planned enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 9th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, or all of them as a file.
02

Study summary

This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.

Read the detailed description

CT-P53, containing the active ingredient ocrelizumab, is a humanized monoclonal antibody that is being developed as a proposed biosimilar medicinal product to Ocrevus. The purpose of this study is to demonstrate similar efficacy, PK, PD and safety of CT-P53 and Ocrevus in patients with Relpasing-remitting Multiple Screlosis.

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDonald criteria.
  • Patient has evidence of recent MS activity as defined in the study protocol
  • Patient has neurological stability for ≥30 days.
  • Patient with 0 to 6.0 (both inclusive) on the EDSS score.

Exclusion criteria

Exclusion Criteria:

  • Patient diagnosed with primary or secondary progressive MS.
  • Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.
  • Patient unable to complete or has a to an MRI
  • Patient with contraindications and/or severe to including methylprednisolone or any of the of study drug or etcs defined in the study protocol.
  • Patient who has currently or history of any of medical conditions described in the study protocol.
  • Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
512 participants (estimated)

Study arms

  • Experimental
    CT-P53

    CT-P53(Ocrelizumab)

    Biological: CT-P53

  • Active comparator
    US-Ocrevus

    US-licensed Ocrevus(Ocrelizumab)

    Biological: US-Ocrevus

  • Active comparator
    EU-Ocrevus

    EU-approved Ocrevus(Ocrelizumab)

    Biological: EU-Ocrevus

Interventions

  • BiologicalCT-P53

    Intravenous(IV) infusion

    Also known as: Ocrelizumab

  • BiologicalUS-Ocrevus

    Intravenous(IV) infusion

    Also known as: Ocrelizumab

  • BiologicalEU-Ocrevus

    Intravenous(IV) infusion

    Also known as: Ocrelizumab

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve in PK group

    To demonstrate PK comparability in terms of the area under the concentration time curve in patients with RRMS as follows: * Area under the concentration-time curve from time zero to Week 2 (AUC0-wk2) * Area under the concentration-time curve from Week 2 to Week 24 (AUCwk2-wk24)

    Time frame: Up to Week 24

  2. Total number of new GdE lesions on T1-weighted brain MRI in Main study group

    To demonstrate the equivalence of CT-P53 to reference drug (EU-Ocrevus and US-Ocrevus) in terms of efficacy in patients with RRMS as determined by the total number of new gadolinium-enhancing (GdE) lesions on T1-weighted brain magnetic resonance imaging (MRI)

    Time frame: Up to Week 24

Secondary outcomes

  1. Absoulte CD19+ B-cell counts for PD assessments

    To assess PD of CT-P53 and reference drug (EU-Ocrevus and US-Ocrevus) as follows: • Absolute CD19+ B-cell counts

    Time frame: Up to Week 96

  2. Area under the concentration-time curve in PK group

    Area under the concentration-time curve from time zero to Week 16

    Time frame: Up to Week 16

  3. Total body clearance in PK group

    Total body clearance covering both administrations at Weeks 0 and 2 (CL)

    Time frame: Up to Week 2

  4. Volume of distribution at steady state in PK group

    Volume of distribution at steady state covering both administrations at Week 0 and 2 (Vss)

    Time frame: Up to Week 2

  5. Safety: Immunogenecity

    Number and percentage of patients with positive antidrug-antibody and neutralizing antibody results

    Time frame: Up to Week 96

  6. Annualized Relapse Rate (ARR)

    The total number of protocol-defined MS relapses for each patient will be counted and listed. Annualized relapse rate (ARR) will be calculated by the total number of protocol-defined relapses for all patients divided by time-in-study by patient.

    Time frame: Up to Week 96

  7. Change in Expanded Disability Status Score (EDSS)

    The EDSS score will be listed and descriptive statistics for actual value and change in EDSS score from baseline to Weeks 24, 48 and 96 will be summarized by treatment group and visit. An increase ≥1.5 point from baseline EDSS score is defined as disability progression. A reduction ≥1.0 point from baseline EDSS score is defined as disability improvement.

    Time frame: Up to Week 96

  8. Change in Multiple Sclerosis Functional Composite Score (MSFCS)

    There are three components to the MSFCS; (1) the average scores of two trials of T25-FW (2) the average scores on the 9-HPT (the two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged) (3) the number of correct answers from the PASAT-3. Multiple Sclerosis Functional Composite Score (MSFCS) is based on the concept that scores for these three dimensions (arm, leg, and cognitive functions) are combined to create a single score (the MSFCS) that can be used to detect change over time in MS patients

    Time frame: Up to Week 96

  9. Total Number of Lesions on Brain Magnetic Resonance Imaging

    The total number of lesions on brain MRI will be calculated as the cumulative sum of the individual number of the lesions at each scheduled visit

    Time frame: Up to Week 96

  10. Volume of Hypointense Lesions on T1-weighted Brain Magnetic Resonance Imaging

    Actual value of volume of hypointense lesions on T1-weighted brain MRI will be listed by treatment group and visit. Descriptive statistics for actual value and change in volume of hypointense lesions on T1-weighted brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group

    Time frame: Up to Week 96

  11. Brain Volume on Brain Magnetic Resonance Imaging

    Change in brain volume is defined as the brain volume at pre-specified time point minus brain volume at baseline. Actual value of brain volume on brain MRI will be listed by treatment group. Descriptive statistics for actual value and percentage change in brain volume on brain MRI from baseline to Weeks 24, 48 and 96 will be summarized by treatment group.

    Time frame: Up to Week 96

  12. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    All reported terms of AEs will be coded to system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) and severity grading of AEs will be recorded according to the CTCAE Version 5.0

    Time frame: Up to Week 96

07

Study locations

1 of 1 sites recruiting
  • CT-P53 3.1 investigational site
    Poznań, Poland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 37 months is close to that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jun 18, 2023
StartActual
Jan 11, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Jan 2029
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05906992
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jan 11, 2024
Primary completion
Feb 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
May 22, 2024

Study contacts

SoYoung Yoo
Contact
soyoung.yoo@celltrion.com
+82 32 850 5791
JinHo Lee
Contact
jinho.lee2@celltrion.com
+82 32 850 5787
Minji Ma
study chair · Celltrion, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion